Clearmind Medicine Common Stock Return On Asset
| CMND Stock | USD 1.30 0.02 1.56% |
Clearmind Medicine Common fundamentals help investors to digest information that contributes to Clearmind Medicine's financial success or failures. It also enables traders to predict the movement of Clearmind Stock. The fundamental analysis module provides a way to measure Clearmind Medicine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clearmind Medicine stock.
As of November 30, 2024, Return On Assets is expected to decline to -3.34. Clearmind | Return On Asset |
Clearmind Medicine Common Company Return On Asset Analysis
Clearmind Medicine's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Clearmind Medicine Return On Asset | -0.58 |
Most of Clearmind Medicine's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clearmind Medicine Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Clearmind Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Clearmind Medicine is extremely important. It helps to project a fair market value of Clearmind Stock properly, considering its historical fundamentals such as Return On Asset. Since Clearmind Medicine's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Clearmind Medicine's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Clearmind Medicine's interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Clearmind Total Assets
Total Assets |
|
Based on the latest financial disclosure, Clearmind Medicine Common has a Return On Asset of -0.5795. This is 93.38% lower than that of the Biotechnology sector and 97.54% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Clearmind Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clearmind Medicine's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clearmind Medicine could also be used in its relative valuation, which is a method of valuing Clearmind Medicine by comparing valuation metrics of similar companies.Clearmind Medicine is currently under evaluation in return on asset category among its peers.
Clearmind Medicine Current Valuation Drivers
We derive many important indicators used in calculating different scores of Clearmind Medicine from analyzing Clearmind Medicine's financial statements. These drivers represent accounts that assess Clearmind Medicine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Clearmind Medicine's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 11.3K | 16.8K | 21.8K | 466.4K | 419.8K | 440.8K | |
| Enterprise Value | 10.6K | (313.0K) | (4.6M) | 343.0K | 394.5K | 414.2K |
Clearmind Fundamentals
| Return On Equity | -2.68 | ||||
| Return On Asset | -0.58 | ||||
| Current Valuation | (2.41 M) | ||||
| Shares Outstanding | 4.07 M | ||||
| Shares Owned By Institutions | 17.31 % | ||||
| Number Of Shares Shorted | 187.57 K | ||||
| Price To Earning | (750.00) X | ||||
| Price To Book | 1.50 X | ||||
| EBITDA | (8.71 M) | ||||
| Net Income | (6.23 M) | ||||
| Cash And Equivalents | 1.65 K | ||||
| Total Debt | 3.61 M | ||||
| Current Ratio | 0.03 X | ||||
| Book Value Per Share | 0.87 X | ||||
| Cash Flow From Operations | (4.56 M) | ||||
| Short Ratio | 0.49 X | ||||
| Earnings Per Share | (1.23) X | ||||
| Beta | -1.51 | ||||
| Market Capitalization | 5.29 M | ||||
| Total Asset | 4.32 M | ||||
| Retained Earnings | (13.63 M) | ||||
| Working Capital | 824.76 K | ||||
| Net Asset | 4.32 M |
About Clearmind Medicine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clearmind Medicine Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearmind Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearmind Medicine Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearmind Medicine Common is a strong investment it is important to analyze Clearmind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearmind Medicine's future performance. For an informed investment choice regarding Clearmind Stock, refer to the following important reports:Check out Clearmind Medicine Piotroski F Score and Clearmind Medicine Altman Z Score analysis. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearmind Medicine. If investors know Clearmind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearmind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Return On Assets (0.58) | Return On Equity (2.68) |
The market value of Clearmind Medicine Common is measured differently than its book value, which is the value of Clearmind that is recorded on the company's balance sheet. Investors also form their own opinion of Clearmind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Clearmind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearmind Medicine's market value can be influenced by many factors that don't directly affect Clearmind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearmind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearmind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearmind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.